Philly's Context Therapeutics Will Now Test Prostate Cancer Drug on Breast Cancer
January 15, 2018
Felix Kim, PhD, an assistant professor in the College of Medicine, was mentioned in a Jan. 15 Philadelphia Inquirer story about the sale of Argo Therapeutics to Context Therapeutics, the startup pharmaceutical company that Kim co-founded in 2015. Context is developing drugs to treat prostate and metastatic breast cancers.
Related:
Drexel News is produced by
University Marketing and Communications.